newsfilter
← Latest News
GlobeNewswire·

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Two-year relapse data from ALLOHA™ Phase 1 heme trial to be presented by end of year Expects to dose first solid tumor patients with multiplex TCR-T in the third quarter of 2025 Cash, cash equivalents, and